PYY plays a key role in the resolution of diabetes following bariatric surgery in humans

Autor: Guida, C, Stephen, SD, Watson, M, Dempster, N, Larraufie, P, Marjot, T, Cargill, T, Rickers, L, Pavlides, M, Tomlinson, J, Cobbold, JFL, Zhao, C-M, Chen, D, Gribble, F, Reimann, F, Gillies, R, Sgromo, B, Rorsman, OP, Ryan, JD, Ramracheya, RD

Publikováno v: EBioMedicine
EBioMedicine, Elsevier, 2019, 40, pp.67-76. ⟨10.1016/j.ebiom.2018.12.040⟩

Background Bariatric surgery leads to early and long-lasting remission of type 2 diabetes (T2D). However, the mechanisms behind this phenomenon remain unclear. Among several factors, gut hormones are thought to be crucial mediators of this effect. Un

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::68ccbb551382b2df1d7e0d97046ca869
https://hal-agroparistech.archives-ouvertes.fr/hal-03451358/document

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PYY plays a key role in the resolution of diabetes following bariatric surgery in humans.

Autor: Guida C; Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, UK., Stephen SD; Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, UK., Watson M; Translational Gastroenterology Unit, University of Oxford, Oxford, UK., Dempster N; Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, UK., Larraufie P; Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK., Marjot T; Translational Gastroenterology Unit, University of Oxford, Oxford, UK., Cargill T; Translational Gastroenterology Unit, University of Oxford, Oxford, UK., Rickers L; Oxford Bariatric Service, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Pavlides M; Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, UK; Oxford NIHR Biomedical Research Centre, Oxford, UK., Tomlinson J; Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, UK., Cobbold JFL; Translational Gastroenterology Unit, University of Oxford, Oxford, UK., Zhao CM; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway., Chen D; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway., Gribble F; Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK., Reimann F; Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK., Gillies R; Oxford Bariatric Service, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Sgromo B; Oxford Bariatric Service, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Rorsman P; Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, UK., Ryan JD; Translational Gastroenterology Unit, University of Oxford, Oxford, UK. Electronic address: john.ryan@ndm.ox.ac.uk., Ramracheya RD; Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, UK. Electronic address: Reshma.ramracheya@ocdem.ox.ac.uk.

Publikováno v: EBioMedicine [EBioMedicine] 2019 Feb; Vol. 40, pp. 67-76. Date of Electronic Publication: 2019 Jan 11.